1
/
의
1
AntibodySystem
SKU(재고 관리 코드):KDE43401
Lirilumab ELISA Kit
Lirilumab ELISA Kit
Catalog No.: KDE43401
| Catalog No. | KDE43401 |
|---|---|
| Product name | Lirilumab ELISA Kit |
| Size | 96 T |
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Detection method | Colorimetric |
| Precision | CV<20% |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 0.156 μg/ml |
| Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Background | Lirilumab (IPH2102/BMS-986015/BMS-986015-01) is a fully human monoclonal antibody (mAb) that is designed to block the interaction between KIR2DL-1,-2,-3 inhibitory receptors and their ligands. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb. A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017. It was registered for a trial for squamous cell carcinoma of the head and neck (SCCHN), but it may be abandoned. On 22 May 2018, a clinical trial for Bladder Cancer was started by PrECOG LLC. |
| Alternative Names | BMS-986015, IPH2102, CAS: 1000676-41-4 |
| Shipping | 2-8 ℃ |
| Note | For Research Use Only. |
Share
